Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the

On Thursday evening, the Los Angeles Lakers beat the Boston Celtics (at home) by a score of 117-96. LeBron James and Anthony Davis combined for 44 points, 22 r

Ben Johnson's first staff with the Chicago Bears is starting to take shape. Johnson has reportedly hired two former NFL players onto his staff with the Chicago Bears, bringing one of those coaches with him from Detroit. Here are the two coaches reportedly joining the Bears' staff under first-year head coach Ben Johnson.

As Chicago Bears head coach Ben Johnson fills out his coaching staff, here are 10 candidates to monitor for key roles with the team.

Savannah's Clay Johnson, lead singer of the Fabulous Equinox Orchestra, competes in the 2025 ATC, the first time in a decade there will be a local contestant

However, fans have criticized the Bears' post because this award came from Johnson's efforts with a direct division rival while also helping Detroit go 2-0 against Chicago. "Bears down so bad they are hyping up their coaches for winning awards with other teams," said one comment.

The Bears are not retaining nicklebacks coach David Overstreet, running backs coach Chad Morton or cornerbacks coach Jon Hoke, according to multiple reports. Hoke helped make Jaylon Johnson an NFL All-Pro cornerback; Overstreet helped develop Kyler Gordon into a standout nickelback.

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its extensive supply chain?

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and challenges as it positions itself for long-term growth. Recent financial reports and analyst assessments paint a picture of a company leveraging its strong oncology portfolio and innovative medicine segment to offset headwinds in other areas.